Why Is Antibiotic Development In The U.S. Disappearing?

By Ed Miseta, Chief Editor, Clinical Leader

Over the last 20 years, the antibiotic industry has been a difficult one for drug developers.

Today, 95 percent of antibiotics in development are being studied by smaller biotechs, including Paratek Pharmaceuticals. Today, the company is on a strong trajectory, but its ups and downs show why antibiotic companies fail and few new antibiotics reach patients.